| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | 5-HIAA |
| Uniprot No | Q9HC97 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-309aa |
| 氨基酸序列 | MNGTYNTCGSSDLTWPPAIKLGFYAYLGVLLVLGLLLNSLALWVFCCRMQQWTETRIYMTNLAVADLCLLCTLPFVLHSLRDTSDTPLCQLSQGIYLTNRYMSISLVTAIAVDRYVAVRHPLRARGLRSPRQAAAVCAVLWVLVIGSLVARWLLGIQEGGFCFRSTRHNFNSMAFPLLGFYLPLAVVVFCSLKVVTALAQRPPTDVGQAEATRKAARMVWANLLVFVVCFLPLHVGLTVRLAVGWNACALLETIRRALYITSKLSDANCCLDAICYYYMAKEFQEASALAVAPSAKAHKSQDSLCVTLA |
| 预测分子量 | 34 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3-4条关于5-HIAA重组蛋白的模拟参考文献示例(非真实文献，仅供格式参考)：
---
1. **文献名称**：*Recombinant TPH1 expression and 5-HIAA production in vitro*
**作者**：Smith A, et al.
**摘要**：研究通过重组人色氨酸羟化酶(TPH1)在哺乳动物细胞中的表达，优化5-羟色胺代谢产物5-HIAA的体外生成体系，为神经内分泌研究提供工具。
2. **文献名称**：*Development of a 5-HIAA-specific ELISA using recombinant antibodies*
**作者**：Li X, et al.
**摘要**：利用重组抗体技术构建高灵敏度的5-HIAA检测方法，应用于类癌综合征患者的生物标志物分析，显著提升检测效率。
3. **文献名称**：*Engineering recombinant AADC enzyme for enhanced 5-HIAA synthesis*
**作者**：Park JH, et al.
**摘要**：通过基因工程改造芳香族L-氨基酸脱羧酶(AADC)，提高其催化5-HTP转化为5-羟色胺的活性，并建立配套的5-HIAA体外代谢模型。
4. **文献名称**：*Structural analysis of 5-HIAA-binding recombinant proteins via cryo-EM*
**作者**：Garcia R, et al.
**摘要**：解析重组表达的5-HIAA结合蛋白的冷冻电镜结构，揭示其与代谢产物的相互作用机制，为靶向药物设计提供依据。
---
注：以上文献为模拟生成，实际研究中需通过PubMed/Google Scholar等平台检索真实文献。
5-HIAA (5-hydroxyindoleacetic acid) is the primary metabolite of serotonin (5-hydroxytryptamine, 5-HT), a neurotransmitter involved in mood regulation, digestion, and circadian rhythms. The quantification of 5-HIAA in biological fluids, particularly urine, serves as a critical diagnostic marker for neuroendocrine tumors, such as carcinoid tumors, which overproduce serotonin. To enable accurate and standardized detection of 5-HIAA in clinical and research settings, recombinant proteins, such as antibodies or enzymes used in immunoassays, have been developed.
Recombinant 5-HIAA-associated proteins are typically produced using genetic engineering techniques. Genes encoding antibodies or enzymes specific to 5-HIAA or its precursors are cloned into expression systems (e.g., E. coli, yeast, or mammalian cells), allowing large-scale production of purified, high-affinity proteins. These proteins are designed to enhance the sensitivity and specificity of assays like ELISA, liquid chromatography-mass spectrometry (LC-MS), or immunochemical tests. For instance, recombinant antibodies targeting 5-HIAA improve diagnostic accuracy by minimizing cross-reactivity with structurally similar molecules.
The development of recombinant 5-HIAA-related proteins addresses challenges in traditional methods, such as batch variability in polyclonal antibodies from animal sources. Recombinant systems ensure consistency, scalability, and ethical compliance. Additionally, they support the creation of novel biosensors and point-of-care devices for rapid 5-HIAA monitoring, aiding early tumor detection and treatment efficacy evaluation. Ongoing research focuses on optimizing protein stability, binding affinity, and cost-effectiveness to further advance clinical diagnostics and serotonin-related metabolic studies.
×
